## <u>Medicare Agrees to Limited Payment for New</u> <u>Alzheimer's Drug</u>



On January 11, 2022, the Centers for Medicare and Medicaid Services (CMS) **released** a proposed National Coverage Determination (NCD) decision memo limiting Medicare coverage for Biogen's new Alzheimer's drug, Aduhelm. Under the terms of the NCD – despite FDA's 2021 approval of the drug – CMS will only pay for Aduhelm for Medicare beneficiaries who are enrolled in a qualifying clinical trial to assess the drug's safety and its effectiveness in slowing the progression of Alzheimer's. CMS **stated**, "[B]ased on the public comments submitted previously and evidence CMS reviewed, the potential for harm, and important questions that remain, we have determined that coverage with evidence development through clinical trials is the right decision for Medicare patients, clinicians, and caregivers, and we look forward to receiving feedback on the proposal." The proposed NCD is **open** to public comment for thirty (30) days, and a final decision from CMS is expected **on April 11**. If the proposed NCD is finalized, CMS must evaluate each submitted clinical trial to verify that it meets the qualifying criteria specified in the proposed NCD.

Aduhelm has been approved by FDA for the treatment of Alzheimer's since June 2021. This is the first drug approved by FDA for the treatment of Alzheimer's in almost 20 years. In 2019, two clinical trials for Aduhelm were **paused** due to data showing the drug was of no benefit to patients' cognitive function. However, after Biogen re-analyzed one of its trials, it decided to apply to the FDA for approval. The FDA used the accelerated approval process but can withdraw Aduhelm from the market if Biogen's new clinical trial demonstrates that the drug is ineffective. The FDA **pivoted** on the approval itself, later **recommending** Aduhelm only in patients with mild cognitive impairment or mild dementia. Patient advocacy groups such as the Alzheimer's Association **played** an important role in pressuring FDA to approve Aduhelm, given the minimal advancements in drug treatment in the space.

Since receiving FDA approval, Biogen has faced tough scrutiny about Aduhelm's efficacy and cost. Aduhelm's initial annual price of \$56,000 elicited widespread criticism. In December 2021, Biogen **announced** that it would reduce the drug's price to \$28,200 for some patients. Biogen most likely reduced the price in response to slower than anticipated sales and CMS's announcement it would increase Medicare's monthly Part B premium for outpatient care in anticipation of the Aduhelm's price impact. Adding to Biogen's challenges, an FDA advisory committee agreed almost **unanimously** that the clinical trials did not provide strong enough evidence to corroborate Aduhelm's efficacy data. However, based on the clinical trials it did review, FDA **claimed** that Aduhelm could reduce clumps of plaque in the brain, which is likely to slow dementia. The discrepancy between the advisory committee's and FDA's findings coupled with broad criticism of the FDA led the Department of Health and Human Services Office of Inspector General to conduct a **probe** into the FDA's approval process for Aduhelm. Adding to the complexity, State Medicaid programs have also been vocal in protesting CMS's decision. Unlike Medicare, Medicaid is required to cover all FDA-approved drugs regardless of a drug's clinical efficacy. Therefore, had Medicare determined not to cover Aduhelm, all costs would **shift** to the state Medicaid programs. Though some states and insurers have already **declined** to cover Aduhelm, CMS's ruling is likely to influence other payors to refuse coverage.

While some commenters and industry observers have questioned whether CMS's decision with respect to Aduhelm somehow creates a new, default secondary clinical testing and approval threshold for drug makers, it is more likely that the Medicare agency's decision on Aduhelm reflects the unique circumstances posed by the drug (*i.e.* unclear efficacy concerns, conflicting FDA guidance, and an unusually high price point). Whether CMS will make a habit of limiting coverage for innovative drugs only to beneficiaries participating in additional clinical trials remains to be seen, but is not likely. We will continue to monitor trends and developments at CMS with respect to coverage and payment decisions on new therapeutics and treatments, including additional research and testing requirements that the agency may impose.

Planning For The End: Goodwin FDA attorneys Steve Tjoe and Susan Lee highlight key takeaways From FDA's draft guidances proposing transition plans for medical devices marketed under EUAs or enforcement policies during the COVID-19 Public Health Emergency



During the COVID-19 public health emergency, the United States Food and Drug Administration (FDA) has issued hundreds of Emergency Use Authorizations (EUAs) and numerous enforcement policies to facilitate the availability of important medical devices. On December 23, 2021, FDA published two draft guidances setting forth the Agency's proposed process for transitioning the multitude of devices brought to market under these circumstances to full compliance with FDA requirements:

- Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (the "EUA Transition Draft Guidance"); and
- Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (the "Enforcement Policies Transition Draft Guidance").

In our **recent Alert**, we summarize some key takeaways from FDA's proposed transition plan for manufacturers of devices marketed under a COVID-19 EUA ("EUA Devices") and devices marketed under one of more than 15 COVID-19 enforcement policies listed in the guidance ("Enforcement Policy Devices"). **Read More** 

# <u>Review of FDA's 2021 Drug Approvals - Small</u> <u>Molecules Dominate</u>



The FDA's Center for Drug Evaluation and Research (CDER)

approved 50 new drugs and biological products in 2021 (not including the vaccines, cellular and gene therapy products, or other products approved in 2021 by the Center for Biologics Evaluation and Research). As in past years, small molecule drug approvals dominated the list.

Of the 50 approved new drugs and biological products, 33 were small molecule drugs and 17 were monoclonal antibodies and other big molecules drugs. A new ADC (antibody drug conjugate) was approved, Tivdak®, and a bispecific antibody was also approved, Rybrevant®. Notably, a small interfering RNA drug was approved, Leqvio®, for the treatment of atherosclerotic cardiovascular disease.

As small and big molecule drugs enter the clinic, Goodwin's patent attorneys focus on securing not only composition of matter patent protection, but additional patent protection derived from clinical data. Learn more about additional patent protection secured from the clinic in <u>Goodwin's Patent</u> <u>Savvy Executive video</u>.

Each new drug and biological product can be found in the FDA's <u>Orange Book</u> or the FDA's <u>Purple</u> <u>Book</u>. To learn more about the Orange Book and how to determine patent terms on approved drugs, visit <u>Goodwin's Patent Savvy Executive video</u>.

See the full list <u>here</u>.

# <u>On Remote Control: FDA Issues Draft</u> <u>Guidance to Facilitate Use of Digital Health</u>

# **Technologies for Remote Data Acquisition in** <u>Clinical Trials</u>



During the COVID-19 pandemic, decentralized clinical trials and remote patient monitoring and data acquisition became a necessity, accelerating the use of digital health technologies in clinical trials. Acknowledging that technological advances "have revolutionized the ability to remotely obtain and analyze clinically relevant information from individuals" and that "DHTs [] are playing a growing role in health care and offer important opportunities in clinical research," the FDA issued during the last week of December 2021 a draft guidance, *Digital Health Technologies for Remote Data Acquisition in Clinical Investigations*, which provides recommendations for sponsors, investigators and other stakeholders to facilitate the use of DHTs for remote data acquisition in clinical trials, including clinical trials that will be submitted to the FDA in a marketing application for a medical product.

The draft guidance defines a digital health technology (DHT) as a system that uses computing platforms (such as a mobile phone, tablet, or smart watch), connectivity, software, and/or sensors for healthcare and related uses. Some DHTs may meet the definition of "device" under the Federal Food, Drug and Cosmetic Act, but the draft guidance specifically does not address the circumstances under which a DHT would meet the statutory definition of a device and notes that DHTs used in clinical investigations generally are exempt from premarket clearance or approval requirements, as long as the clinical investigation is compliant with 21 CFR Part 812.

The draft guidance explains that sponsors must foremost ensure that a DHT is "**fit-for-purpose**" for its proposed use in a specific clinical investigation. In essence, the level of verification and validation associated with the DHT must be sufficient to support its use and interpretability in the clinical investigation. This may require sponsors to work with the developer or manufacturer of the DHT, patients, caregivers, and other technical and clinical experts to assure that the DHT is suitable for its intended purpose in the clinical investigation. The draft guidance advises sponsors to select a DHT that corresponds to the clinical outcome to be assessed, and that considers the clinical trial population and the design/operating characteristics of the DHT that may affect trial participants' use of the DHT.

Sponsors should also be prepared to describe how they will analyze data collected from DHTs in their statistical analysis plan, including prespecifying "**intercurrent events**" (defined as events that occur after treatment initiation that result in missing or erroneous data associated with the clinical outcome of interest) that may be related to the DHT and/or the general purpose computing platform, and how these events will be accounted for in the analysis. To maintain data integrity, FDA recommends that the output of the DHT and associated metadata be transmitted to a **durable electronic data repository** that is protected from alterations and maintained until the end of the record retention period. FDA generally will consider data in such a repository to constitute the

source data and should be made available for inspection and to reconstruct and evaluate the clinical investigation.

FDA further notes that "unique privacy risks" may arise when DHTs are used in a clinical trial. Sponsors are advised to evaluate the risk of potential disclosures of personally identifiable information through breaches of the DHT, the general computing platform on which the DHT runs, and/or the durable electronic repository, assure appropriate security safeguards are in place, and consider including such information in the informed consent documents for the clinical trial.

The draft guidance recommends that sponsors:

- train trial participants and trial personnel on the use of DHTs and develop a plan to provide technical assistance to trial participants and study personnel;
- develop a risk management plan to address potential problems with the DHT (e.g., interference between mobile applications, or loss, damage and replacement);
- develop a safety monitoring plan that addresses how abnormal measurements related to participants' safety measured by DHTs will be reviewed and managed; and
- develop a contingency plan for any changes to the DHT (e.g., discontinuation of a specific model, operating system updates)

The draft guidance includes appendices with specific examples of how different types of DHTs could be incorporated into a clinical investigation. Given the particular circumstances of each DHT and clinical investigation, the draft guidance encourages sponsors to engage early with the appropriate FDA Center responsible for the medical product under development to discuss the proposed use of DHT(s) in a clinical investigation and, for DHTs or DHT-collected endpoints that require qualification, engage with an appropriate FDA qualification program, such as the <u>Medical Device</u> <u>Development Tool Qualification Program</u>.

**<u>Comments</u>** on the draft guidance are due March 23, 2022.

**Reality Check: FDA Draft Guidance Outlines Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drugs and Biological Products** 



Last week the FDA issued another draft guidance in its series of recent guidance documents setting forth the agency's views regarding the generation and use of Real-World Data (RWD) and Real-World Evidence (RWE) for prescription drugs and biological products. (see our <u>recent post</u> on FDA's draft guidance relating to registries).

This latest draft guidance, <u>Considerations for the Use of Real-World Data and Real-World</u> <u>Evidence to Support Regulatory Decision-Making for Drug and Biological Products</u>, clarifies the agency's expectations for sponsors submitting new drug applications (NDAs) or biologics license applications (BLAs) with studies using Real-World Data (RWD) to support the safety or effectiveness of drugs or biological products, when such studies are not subject to FDA's investigational new drug (IND) application requirements under <u>21 CFR Part 312</u>. The draft guidance focuses on noninterventional (*a.k.a.* observational) studies, in which patients receive a drug during routine medical practice, according to a medical provider's clinical judgment and based on patient characteristics, rather than via assignment to a study arm and according to a clinical trial protocol.

Key considerations outlined in the guidance:

- Sponsors designing a non-interventional study to support a marketing application should engage early with the relevant FDA review division (e.g., through a Type C meeting) and be prepared to submit draft protocols and SAPs for FDA feedback before conducting the study analyses.
- To assure the FDA that the results of a non-interventional study were not skewed to favor a particular conclusion, sponsors should provide evidence that the non-interventional study protocol and statistical analysis plan were finalized *prior* to reviewing outcome data and *before* performing prespecified analyses. Sponsors should provide a justification for selecting relevant data sources and generate audit trails in their datasets. FDA also recommends that sponsors post their non-interventional study protocols on a publicly available website, such as <u>ClinicalTrials.gov</u>.
- Sponsors must be able to submit patient-level data from the RWD. Where a third party owns or controls the RWD, sponsors should have agreements with such parties to ensure that patient-level data and source data to verify the RWD can be provided to the FDA for inspection, as applicable. Sponsors should have well-documented programming codes and algorithms that would allow the FDA to replicate the study analysis using the same dataset and analytic approach.
- *Non-interventional studies should be monitored.* The FDA advises sponsors to use a risk-based quality management approach, with a focus on preventing or mitigating important and/or likely risks to study quality. If a non-interventional study does not include any activities or procedures involving patients, monitoring can focus on assuring the data integrity of the RWD, from extraction to analysis to reporting of results. When a non-interventional study protocol includes ancillary activities or procedures, sponsors should exercise appropriate oversight of processes critical to human subject protection.

- Adverse events that a sponsor becomes aware of through a non-interventional study must be submitted in accordance with postmarketing safety reporting regulations. However, the agency acknowledges that if a sponsor is conducting a non-interventional study that appropriately utilizes only a subset of a larger dataset, the sponsor will not have to search the entirety of the dataset for adverse events.
- Sponsors should take responsibility for all activities related to the design, conduct and oversight of a non-interventional study that is being submitted for regulatory review. This includes selecting qualified researchers, ensuring the study is conducted in accordance with the protocol, maintaining and retaining adequate study records, and maintaining an electronic system to manage RWD that complies with **21 CFR Part 11**. Where a sponsor engages third parties to perform certain study-related tasks, the responsibilities of each organization should be documented and made readily available to the FDA upon request.

#### Comments on the guidance should be submitted to the <u>docket</u> by March 9, 2022.

### <u>3 Key Considerations for Promoting</u> <u>Transparency for AI/ML-Enabled Medical</u> <u>Devices</u>



Today, developers of innovative medical devices are increasingly utilizing artificial intelligence (AI) and machine learning (ML) technologies to derive important insights with the promise of transforming the delivery of healthcare. Yet, concerns regarding the transparency of AI/ML-enabled devices, or the degree to which information about such devices is communicated to stakeholders, threatens not only perceptions as to the safety and effectiveness of such devices by regulators, but also trust in such technologies from patients and healthcare providers alike.

Read the full **article** written by **Steven Tjoe** in *PM360 Magazine*.

Visit the **<u>Goodwin on Medtech hub</u>** to stay informed on important developments affecting medtech innovators and investors.

### <u>It's Starting to Register: FDA Draft Guidance</u> <u>Addresses Use of Registries to Support</u> <u>Regulatory Decision-Making for Drugs &</u> <u>Biological Products</u>



Showing no signs of food coma, the FDA issued <u>draft guidance</u> on the Monday following the Thanksgiving holiday weekend that outlines considerations for sponsors proposing to design a registry or use an existing registry to support regulatory decision-making about a drug's effectiveness or safety. This draft guidance represents the Agency's latest response to the mandate in the 21<sup>st</sup> Century Cures Act to issue guidance on the use of real world evidence in regulatory decision-making, and expands on the Framework for FDA's Real-World Evidence Program from December 2018.

The draft guidance, *Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products*, defines a registry as "an organized system that collects clinical and other data in a standardized format for a population defined by a particular disease, condition, or exposure," and identifies three general categories of registries: disease registries, health service registries, and product registries.

Given the range of registry types, FDA notes that registry data can have varying degrees of suitability for use in a regulatory context depending on several factors, including how the data are intended to be used for regulatory purposes, the patient population enrolled, the data collected, and how registry datasets are created, maintained, curated, and analyzed. FDA advises sponsors to be mindful of both the strengths and limitations of using registries as a source of data to support regulatory decision-making. In general, the draft guidance advises that (i) a registry that captures objective endpoints, such as death or hospitalization, is more likely to be suitable to support regulatory decision-making than a registry that collects subjective endpoints, such as pain; and (ii) a registry that is specifically designed to answer a particular research question is more likely to be useful to support regulatory decision-making than a registry that was designed for a different purpose.

At the same time, the Agency acknowledges that an existing registry can be used to collect data for purposes other than those originally intended, and that leveraging an existing registry's infrastructure to support multiple purposes can be efficient. Therefore, the draft guidance describes factors sponsors can use to assess the **relevance** and **reliability** of a registry's data to determine whether the registry data may be fit-for-use.

When determining **relevance** of registry data, the draft guidance advises sponsors to consider, among other things, whether the data elements captured by the registry are sufficient given the intended use or uses of the registry (e.g., external control arm vs. a tool to enroll participants in an

interventional study) and whether the methods involved in patient selection may have impacted the representativeness of the population in the registry.

When assessing the **reliability** of registry data, the draft guidance advises sponsors to assure the registry has appropriate governance measures in place to help ensure the registry can meet its objectives, such as processes and procedures governing the operation of the registry, adequate training of staff, and other recommended practices including:

- Defined processes and procedures for data collection, management and storage;
- A data dictionary and rules for validation of queries and edit checks of registry data;
- Conformance with <u>21 CFR part 11</u>, as applicable, including access controls and audit trails; and
- Adherence to applicable human subject protection requirements, including safeguarding the privacy of patient health information.

The draft guidance specifically recommends that sponsors interested in using a registry to support a regulatory decision should meet with the relevant FDA review division (e.g., through a Type C meeting), *before* conducting a study that will include registry data. Sponsors also should be prepared to submit protocols and statistical analysis plans for FDA feedback prior to conducting a study that includes data from registries.

#### Comments on the guidance should be submitted to the <u>docket</u> by February 28, 2022.

# **Things for Pharma and Biotech Companies to Watch in the Cures 2.0 Proposed Legislation**



Last week, Diana DeGette (D-CO) and Fred Upton (R-MI) introduced in the House highly anticipated bill language for "Cures 2.0", a follow-up to the transformational 21<sup>st</sup> Century Cures Act enacted in 2016. For full text of the bill, click <u>here</u>. The 21<sup>st</sup> Century Cures Act included a variety of measures seeking to accelerate medical product development and bring advancements and innovations to patients more efficiently. Cures 2.0 seeks to improve and expand on those strides, as well as address pressing public health priorities that became apparent through the COVID-19 pandemic.

The Cures 2.0 bill is structured around five main topics:

- Title I—Public Health
- Title II—Patients and Caregivers
- Title III—Food and Drug Administration
- Title IV—Centers for Medicare & Medicaid Services
- Title V—Research

While all of these sections are ripe for further analysis, we selected a few provisions to highlight here that may be of particular interest for the pharmaceutical and biotechnology companies out there. We'll keep tracking these as the bill moves through the legislative process:

Section 204: Patient Experience Data

- Would require sponsors developing a drug under an IND to collect standardized patient experience data during clinical trials and include that patient experience data "and such related data" in an NDA or BLA; and
- Would direct FDA to consider this patient experience data and "related information" in its approval decision for the NDA or BLA.
- These proposals to standardize and require patient experience data collection could be significant, and they underscore lawmakers' continued interest in elevating the relevance of clinical outcomes that are meaningful to patients living with a disease or condition.

Section 302: Grants for Novel Trial Designs and Other Innovations in Drug Development & Section310: Recommendations to Decentralize Clinical Trials

- Section 302 would appropriate \$25 million annually, for 3 years, for the FDA to award grants to clinical trials conducted under an IND with protocols incorporating complex adaptive or other novel trial designs and that collect patient experience data. The section further specifies that grant awards should prioritize the incorporation of digital health technologies and real world evidence.
- Section 310 proposes a multi-stakeholder meeting, including industry representatives and patient advocacy groups, to discuss incentives to adopt decentralized clinical trials. The section also would adopt a definition of decentralized trials: "a clinical trial method that includes the use of telemedicine or digital technologies to allow for the remote collection of clinical trial data from subjects, including in the home or office setting."
- These provisions reflect a sustained emphasis on fostering clinical trial innovation, including building on the experience with remote clinical trials during the COVID-19 pandemic.

**Section 304:** Increasing Use of Real World Evidence (RWE) & **Section 309:** Post-Approval Study Requirements for Accelerated Approval

- Section 304 would call for new guidance on the use of RWE in post-market review of drugs that were designated as a breakthrough therapy or fast track product, or considered for accelerated approval. Section 309 would further specify that the post-approval study requirements to verify and describe the clinical benefit for products granted accelerated approval could be satisfied through RWE, including analyses of data in clinical care repositories or patient registries.
- Section 304 also would establish a permanent Real World Evidence Task Force to coordinate programs and activities within the Department of Health and Human Services related to the collection and use of RWE.
- These and other sections of Cures 2.0 share a common theme of enhancing the use of RWE in regulatory decision-making. Although the inherent variability in RWE likely will continue to present challenges to doing so, the signal is clear that legislators would like to see FDA and HHS continue to move forward in this area.

Last week's introduction of Cures 2.0 and President Biden's announcement that he will nominate Robert Califf for FDA Commissioner contributed to a newsworthy week for those of us who follow the FDA. We look forward to seeing how Cures 2.0 develops and how the Agency's policy priorities unfold in the coming months.

### FDA Issues Guiding Principles for Good Machine Learning Practice for Medical Device Development



On October 27, 2021, the U.S. Food and Drug Administration (FDA), Health Canada and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) **issued** a set of ten guiding principles meant to aid the development of Good Machine Learning Practice (GMLP).

Artificial intelligence and machine learning (AI/ML) offers the potential to analyze the vast amount of real-world data generated from health care every day to provide transformative insights. These insights can not only help improve individual product design and performance, but also hold the promise of transforming health care.

However, AI/ML technology has unique complexities and considerations. The goal of these guiding principles is to help promote safe, effective, and high-quality medical devices that use AI/ML to best cultivate the future of this rapidly progressing field.

Although not formal or binding, as companies continue to leverage AI/ML in their medical devices, they should remain mindful of each of the ten guiding principles:

#### 1. Leveraging Multi-Disciplinary Expertise Throughout the Total Product Life Cycle

Companies should leverage internal and external multi-disciplinary expertise to ensure they have a thorough understanding of the model's integration into the clinical workflow, and the desired benefits and associated patient risks, to ensure the safety and effectiveness of the device while serving clinically meaningful needs throughout the product lifecycle.

#### 2. Implementing Good Software Engineering and Security Practices

Companies should implement as part of model design data quality assurance, data management, good software engineering practices, and robust cybersecurity practices.

# 3. Utilizing Clinical Study Participants and Data Sets that Are Representative of the Intended Patient Population

Companies should ensure that their data collection protocols have sufficient representation of relevant characteristics of the intended patient population, use, and measurement inputs in an adequate sample size in their clinical study and training and

test datasets so that results can reasonably be generalized to the population of interest. Data collection protocols appropriate for the intended patient population may help to identify where the model may underperform and may mitigate bias.

#### 4. Keeping Training Sets and Test Sets Independent

Companies should consider and address all sources of dependence between the training and test datasets, including patient, data acquisition, and site factors to guarantee independence.

#### 5. Selecting Reference Datasets Based Upon Best Available Methods

Companies should use accepted, best available methods for developing a reference dataset, *i.e.*, a reference standard, to ensure clinically relevant and well characterized data are collected (and that the reference's limitations are understood). Where available, companies should use accepted reference datasets in model development and testing that promote and demonstrate model robustness and generalizability across the target population.

# 6. Tailoring Model Design to the Available Data and Reflecting the Intended Use of the Device

Companies should have a solid understanding of the clinical benefits and risks related to the product and utilize this understanding to create clinically meaningful performance goals. Additionally, companies should ensure the model design is suited to the available data and supports active mitigation of the known risks.

#### 7. Focusing on the Performance of the Human-AI Team

Where the model has a human element, companies should consider human factors and human interpretability of the model outputs.

#### 8. Testing Demonstrates Device Performance during Clinically Relevant Conditions

Companies should develop statistically sound tests and execute them to assess device performance data independent of the training data set. Such assessment should be conducted in clinically relevant conditions with consideration given to the intended use population, important subgroups, clinical environment and use by the Human AI-Team, measurement inputs, and potential confounding factors.

#### 9. Providing Users Clear, Essential Information

Companies should provide users ready access to clear, contextually relevant information that is appropriate for the target audience. Such information includes not only information pertaining to the product's intended use and indications for use, performance of the model for appropriate subgroups, characteristics of the data used to train and test the model, acceptable inputs, known limitations, user interface interpretation, and clinical workflow integration of the model, but also users should be made aware of device modifications, updates from real-world performance monitoring, the basis for decision-making (when available), and a way to communicate product concerns to the company.

#### 10. Monitoring Deployed Models for Performance and Managing Re-Training Risks

Companies should deploy models that are capable of being monitored in real-world usage with a focus on maintaining or improving safety and performance. Further, when models are trained after deployment, companies should ensure there are appropriate controls in place to manage risks that may impact the safety and performance of the model.

FDA's expectations with respect to GMLP will continue to advance and become more granular as additional stakeholder input is considered. The docket for FDA's GMLP Guiding Principles, **FDA-2019-N-1185**, is open for public comment.

Visit the **Goodwin on Medtech hub** to stay informed on important developments affecting medtech innovators and investors.

# **Field Alert Reporting: Supplier Contracting Implications for Drug Developers**



For emerging companies establishing their first supply

chains, ensuring notification requirements in supply agreements for when commercial-stage manufacturing issues arise may not be top of mind. However, it is important for drug developers whose contracts enable continuation of a supply arrangement into the commercial-stage to be familiar with the U.S. Food and Drug Administration's (FDA's) field alert reporting (FAR) requirements for new drug application (NDA) and abbreviated new drug application (ANDA) holders to ensure adequate communication between developers and their suppliers.

By way of background, the FAR regulations at 21 C.F.R. §§ 314.81(b)(1) and 314.98(b) require NDA and ANDA holders to notify their FDA field office (using an Form FDA 3331a) within three business days of "receipt" of: (1) information concerning any incident that causes a distributed drug product or its labeling to be mistaken for, or applied to, another article; or (2) information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug product, or any failure of one or more distributed batches of the drug product to meet the specification established for it in its approved application. In brief, timely notification by suppliers really *does matter* here and should not extend past one business day if at all possible.

This past summer, the FDA issued <u>final guidance</u> clarifying reporting timelines and the facts and circumstances that trigger submission of FARs. Amongst other things, the FDA clarified that the FAR requirements apply to *all* products marketed under an NDA or ANDA, including positron emission tomography drugs, designated medical gases, and combination products containing a drug constituent part. However, products that are only marketed abroad pursuant to a foreign approval with non-U.S. labeling are not subject to FDA's FAR requirements. FDA also clarified that report-triggering events are not limited to active ingredient issues but can also include issues related to

inactive ingredients, processing aids, and packaging.

Additional key takeaways include:

- FARs are required even when a problem is identified and corrected within the three business day reporting window.
- FARs are required even when a problem is identified beyond the three business day reporting window; however, a Form FDA 483 finding can result from the failure to submit timely FARs.
- Day "0" for calculation of the three business day reporting window is the day information triggering the report was received, *even if received by a third-party contractor or supplier*.
- Follow-up or final FARs are recommended but not required if significant new information is received.
- Separate initial FARs are required for a problem impacting drug products covered by multiple applications, but if conducting a single investigation into the issue after submitting the initial FARs, any follow-up can be provided in a single follow-up or final FAR.
- Investigations into issues identified with undistributed products should consider whether those issues may exist in distributed products, triggering a FAR.
- Possible changes or deterioration in distributed products triggering FARs include contamination by bacteria, yeast, mold, virus or other microorganisms.
- Issues leading to recalls do not release an NDA or ANDA holder from FAR reporting responsibility.

Overall, FDA's FAR requirements necessitate prompt or immediate notification of any information discovered by suppliers that could trigger a FAR for NDA and ANDA holders. For supplier agreement negotiations, requiring prompt or immediate notification of issues in clinical-stage agreements positions a developer well to require the same in the commercial stage when FAR requirements apply. Additionally, in the commercial stage, FARs can prompt unannounced FDA for cause inspections and can also lead to expensive product recalls, so early notification, investigation, and remediation of issues warranting a FAR submission can help minimize potential liability and resource expenditure to remedy any issues that arise.